Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Losartan | hsa00030 | Pentose phosphate pathway | 1.69E-02 | 2 | P60891, P37837 | PRPS1, TALDO1 | More | | Losartan | hsa00040 | Pentose and glucuronate interconversions | 3.53E-02 | 1 | O60701 | UGDH | More | | Losartan | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Losartan | hsa00071 | Fatty acid degradation | 3.65E-03 | 4 | O75521, P00325, P11766, P33121 | ECI2, ADH1B, ADH5, ACSL1 | More | | Losartan | hsa00220 | Arginine biosynthesis | 2.86E-02 | 2 | P15104, P05089 | GLUL, ARG1 | More | | Losartan | hsa00280 | Valine, leucine and isoleucine degradation | 4.31E-02 | 2 | P26440, Q02252 | IVD, ALDH6A1 | More | | Losartan | hsa00500 | Starch and sucrose metabolism | 1.89E-06 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Losartan | hsa00520 | Amino sugar and nucleotide sugar metabolism | 2.24E-02 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | | Losartan | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 1.91E-02 | 1 | Q9NY97 | B3GNT2 | More | | Losartan | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Losartan | hsa00591 | Linoleic acid metabolism | 1.29E-03 | 1 | P11712 | CYP2C9 | More | | Losartan | hsa00601 | Glycosphingolipid biosynthesis - lacto and neolacto series | 3.78E-02 | 1 | Q9NY97 | B3GNT2 | More | | Losartan | hsa00630 | Glyoxylate and dicarboxylate metabolism | 4.84E-04 | 3 | P40925, P40926, P15104 | MDH1, MDH2, GLUL | More | | Losartan | hsa00730 | Thiamine metabolism | 5.65E-05 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Losartan | hsa00770 | Pantothenate and CoA biosynthesis | 2.26E-04 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | | Losartan | hsa00830 | Retinol metabolism | 2.20E-02 | 4 | P00325, P11766, Q9BPW9, O75911 | ADH1B, ADH5, DHRS9, DHRS3 | More | | Losartan | hsa00860 | Porphyrin and chlorophyll metabolism | 1.70E-04 | 3 | P36551, P53004, P30043 | CPOX, BLVRA, BLVRB | More | | Losartan | hsa00970 | Aminoacyl-tRNA biosynthesis | 1.58E-04 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | Losartan | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Losartan | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Losartan | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | | Losartan | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | | Losartan | hsa01210 | 2-Oxocarboxylic acid metabolism | 1.91E-02 | 1 | P50213 | IDH3A | More | | Losartan | hsa01230 | Biosynthesis of amino acids | 3.59E-02 | 3 | P60891, Q99707, P37837 | PRPS1, MTR, TALDO1 | More | | Losartan | hsa01240 | Biosynthesis of cofactors | 2.05E-02 | 2 | P36551, O60701 | CPOX, UGDH | More | | Losartan | hsa01523 | Antifolate resistance | 2.24E-02 | 3 | P41439, P41440, P01375 | FOLR3, SLC19A1, TNF | More | | Losartan | hsa01524 | Platinum drug resistance | 1.13E-02 | 5 | P10415, Q13489, P78417, P23025, P43246 | BCL2, BIRC3, GSTO1, XPA, MSH2 | More | | Losartan | hsa03008 | Ribosome biogenesis in eukaryotes | 1.31E-04 | 7 | Q9NYH9, O14980, O60832, P78345, Q9BVP2, O15381, Q9GZY0 | UTP6, XPO1, DKC1, RPP38, GNL3, NVL, NXF2; NXF2B | More | | Losartan | hsa03010 | Ribosome | 1.53E-05 | 8 | P62753, P62906, P46776, Q07020, P61513, P27635, P62249, P23396 | RPS6, RPL10A, RPL27A, RPL18, RPL37A, RPL10, RPS16, RPS3 | More | | Losartan | hsa03013 | RNA transport | 1.20E-07 | 14 | O14980, P52298, Q09161, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q14240, P23588, Q9Y6A5, P51114 | XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, EIF4A2, EIF4B, TACC3, FXR1 | More | | Losartan | hsa03020 | RNA polymerase | 5.61E-04 | 3 | P30876, P24928, P62487 | POLR2B, POLR2A, POLR2G | More | | Losartan | hsa03040 | Spliceosome | 3.61E-05 | 13 | Q14562, O43143, O60508, Q99633, P17844, P08579, P51991, P61978, Q13595, Q01130, Q9UMS4, P11142, O43447 | DHX8, DHX15, CDC40, PRPF18, DDX5, SNRPB2, HNRPA3, HNRPK, TRA2A, SFRS2, PRPF19, HSPA8, PPIH | More | | Losartan | hsa03050 | Proteasome | 4.83E-02 | 1 | P55036 | PSMD4 | More | | Losartan | hsa03060 | Protein export | 4.42E-02 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | | Losartan | hsa03320 | PPAR signaling pathway | 4.33E-02 | 2 | Q6PCB7, Q9UNU6 | SLC27A1, CYP8B1 | More | | Losartan | hsa03450 | Non-homologous end-joining | 4.32E-02 | 1 | Q9NP87 | POLM | More | | Losartan | hsa04012 | ErbB signaling pathway | 3.31E-02 | 1 | Q13153 | PAK1 | More | | Losartan | hsa04015 | Rap1 signaling pathway | 1.58E-02 | 6 | P20827, P49767, P63261, P25116, P0DP23, P17252 | EFNA1, VEGFC, ACTG1, F2R, CALM1, PRKCA | More | | Losartan | hsa04020 | Calcium signaling pathway | 1.16E-03 | 7 | Q16566, P17252, O15399, P25116, P0DP23, P23634, P49767 | CAMK4, PRKCA, GRIN2D, F2R, CALM1, ATP2B4, VEGFC | More | | Losartan | hsa04022 | cGMP-PKG signaling pathway | 2.55E-02 | 4 | P18848, Q8WYR1, P05141, P0DP24 | ATF4, PIK3R5, SLC25A5, CALM2 | More | | Losartan | hsa04024 | cAMP signaling pathway | 7.32E-03 | 6 | P0DP23, P23634, Q16566, O15399, P25116, Q13153 | CALM1, ATP2B4, CAMK4, GRIN2D, F2R, PAK1 | More | | Losartan | hsa04060 | Cytokine-cytokine receptor interaction | 1.52E-04 | 19 | P27930, P14778, P37173, P26842, Q9UHF4, Q13651, P16871, P78552, P25024, Q9UBD3, P47992, P02775, P09341, P32248, P80075, P51684, P18510, P09603, P01730 | IL1R2, IL1R1, TGFBR2, CD27, IL20RA, IL10RA, IL7R, IL13RA1, CXCR1, XCL2, XCL1, PPBP, CXCL1, CCR7, CCL8, CCR6, IL1RN, CSF1, CD4 | More | | Losartan | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 2.08E-04 | 11 | P51684, P32248, P09341, P19875, P25024, P02775, P25025, P47992, Q9UBD3, P14784, Q9UHF4 | CCR6, CCR7, CXCL1, CXCL2, CXCR1, PPBP, CXCR2, XCL1, XCL2, IL2RB, IL20RA | More | | Losartan | hsa04062 | Chemokine signaling pathway | 2.43E-04 | 14 | P25024, P25025, P09341, P19875, P47992, Q9UBD3, P07948, P42338, P19174, P63218, P50151, P49407, Q08881, P49841 | CXCR1, CXCR2, CXCL1, CXCL2, XCL1, XCL2, LYN, PIK3CB, PLCG1, GNG5, GNG10, ARRB1, ITK, GSK3B | More | | Losartan | hsa04064 | NF-kappa B signaling pathway | 1.36E-06 | 21 | P10415, P51617, O00463, Q13546, P14778, P01584, P01375, P19174, Q04759, Q9UDY8, Q13077, Q16548, P06239, Q8WV28, P63279, P24522, Q8NHW4, P09341, P19875, Q06643, Q9NQC7 | BCL2, IRAK1, TRAF5, RIPK1, IL1R1, IL1B, TNF, PLCG1, PRKCQ, MALT1, TRAF1, BCL2A1, LCK, BLNK, UBE2I, GADD45A, CCL4L2, CXCL1, CXCL2, LTB, CYLD | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P51684 | CCR6 | C-C chemokine receptor type 6 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.84 | P51684 | CCR6 | C-C chemokine receptor type 6 | P51617 | IRAK1 | Interleukin-1 receptor-associated kinase 1 | 0.722 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.932 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.837 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q13546 | RIPK1 | Receptor-interacting serine/threonine-protein kinase 1 | -0.868 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.766 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.76 | Q13547 | HDAC1 | Histone deacetylase 1 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.854 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01584 | IL1B | Interleukin-1 beta | 0.807 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P01584 | IL1B | Interleukin-1 beta | 0.799 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01375 | TNF | Tumor necrosis factor | 0.78 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | Q13547 | HDAC1 | Histone deacetylase 1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.723 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | 0.869 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.796 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.73 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | 0.768 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.958 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.875 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q8WV28 | BLNK | B-cell linker protein | -0.704 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q8WV28 | BLNK | B-cell linker protein | -0.816 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | P63279 | UBE2I | SUMO-conjugating enzyme UBC9 | 0.756 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.819 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.796 | P51684 | CCR6 | C-C chemokine receptor type 6 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.712 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.802 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q8NHW4 | CCL4L2 | C-C motif chemokine 4-like | 0.802 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09341 | CXCL1 | Growth-regulated alpha protein | 0.788 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P09341 | CXCL1 | Growth-regulated alpha protein | 0.7 | Q13547 | HDAC1 | Histone deacetylase 1 | P09341 | CXCL1 | Growth-regulated alpha protein | -0.736 | Q13547 | HDAC1 | Histone deacetylase 1 | P19875 | CXCL2 | C-X-C motif chemokine 2 | -0.862 | Q13547 | HDAC1 | Histone deacetylase 1 | Q06643 | LTB | Lymphotoxin-beta | 0.74 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q9NQC7 | CYLD | Ubiquitin carboxyl-terminal hydrolase CYLD | 0.799 | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | Q9NQC7 | CYLD | Ubiquitin carboxyl-terminal hydrolase CYLD | 0.825 |
| Losartan | hsa04066 | HIF-1 signaling pathway | 3.40E-02 | 3 | Q09472, P07195, P10415 | EP300, LDHB, BCL2 | More | | Losartan | hsa04068 | FoxO signaling pathway | 3.52E-02 | 1 | Q96BR1 | SGK3 | More | | Losartan | hsa04070 | Phosphatidylinositol signaling system | 4.07E-02 | 4 | P0DP23, Q14643, O14732, P17252 | CALM1, ITPR1, IMPA2, PRKCA | More | | Losartan | hsa04071 | Sphingolipid signaling pathway | 1.82E-06 | 11 | P17252, P21453, Q9H228, P01375, Q13362, Q16537, Q9BX95, Q16539, P04637, P10415, Q9UQC2 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, PPP2R5E, SGPP1, MAPK14, TP53, BCL2, GAB2 | More | | Losartan | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | | Losartan | hsa04110 | Cell cycle | 2.06E-02 | 6 | Q9UJX4, O60566, Q09472, P24522, P04637, P49918 | ANAPC5, BUB1B, EP300, GADD45A, TP53, CDKN1C | More | | Losartan | hsa04114 | Oocyte meiosis | 6.23E-03 | 5 | Q9Y6D9, P51812, Q02750, P16298, Q17RY0 | MAD1L1, RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | Losartan | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | | Losartan | hsa04136 | Autophagy - other | 5.92E-03 | 2 | O94817, Q9H1Y0 | ATG12, ATG5 | More | | Losartan | hsa04141 | Protein processing in endoplasmic reticulum | 2.82E-04 | 8 | P18848, Q15437, Q15436, Q99941, P11142, P07900, Q9NR31, P14625 | ATF4, SEC23B, SEC23A, CREBL1, HSPA8, HSP90AA1, SAR1A, HSP90B1 | More | | Losartan | hsa04142 | Lysosome | 1.46E-02 | 7 | P06865, P22304, P38571, Q13510, P07602, Q9NRA2, P61916 | HEXA, IDS, LIPA, ASAH1, PSAP, SLC17A5, NPC2 | More | | Losartan | hsa04144 | Endocytosis | 2.89E-03 | 8 | P0DMV8, Q9H444, O75351, P62491, Q96B97, Q15438, Q14161, Q9UMY4 | HSPA1A, CHMP4B, VPS4B, RAB11A, SH3KBP1, PSCD1, GIT2, SNX12 | More | | Losartan | hsa04145 | Phagosome | 1.06E-03 | 11 | O75015, P63261, Q15080, Q13509, P68371, Q13488, P05164, O60603, P35443, P27824, P13765 | FCGR3B, ACTG1, NCF4, TUBB3, TUBB2C, TCIRG1, MPO, TLR2, THBS4, CANX, HLA-DOB | More | | Losartan | hsa04151 | PI3K-Akt signaling pathway | 1.09E-05 | 12 | P62753, O43521, P27348, P07900, P14625, Q8WYR1, Q16363, P22105, Q99941, P18848, O00141, Q6ZUJ8 | RPS6, BCL2L11, YWHAQ, HSP90AA1, HSP90B1, PIK3R5, LAMA4, TNXB, CREBL1, ATF4, SGK, PIK3AP1 | More | | Losartan | hsa04210 | Apoptosis | 3.78E-05 | 14 | P04637, P10415, O76075, P01375, Q9NR28, O75460, P24522, Q16548, Q13077, O43521, P43234, Q9UBR2, P18848, Q14643 | TP53, BCL2, DFFB, TNF, DIABLO, ERN1, GADD45A, BCL2A1, TRAF1, BCL2L11, CTSO, CTSZ, ATF4, ITPR1 | More | | Losartan | hsa04211 | Longevity regulating pathway | 2.72E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | | Losartan | hsa04213 | Longevity regulating pathway - multiple species | 2.70E-03 | 7 | P42338, Q9Y4H2, Q08828, P51828, P0DMV8, P11142, Q13547 | PIK3CB, IRS2, ADCY1, ADCY7, HSPA1A, HSPA8, HDAC1 | More | | Losartan | hsa04217 | Necroptosis | 3.89E-04 | 9 | P01375, P48023, Q14765, P15104, P05141, P01584, P0C0S5, Q99878, Q9H444 | TNF, FASLG, STAT4, GLUL, SLC25A5, IL1B, H2AFZ, H2AC14, CHMP4B | More | | Losartan | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.21E-03 | 9 | P51828, Q99941, P18848, Q16537, P0DP23, Q13557, P17252, P10415, P20020 | ADCY7, CREBL1, ATF4, PPP2R5E, CALM1, CAMK2D, PRKCA, BCL2, ATP2B1 | More | | Losartan | hsa04270 | Vascular smooth muscle contraction | 6.96E-03 | 6 | P0DP23, Q08828, P51828, P35579, P35749, P35318 | CALM1, ADCY1, ADCY7, MYH9, MYH11, ADM | More | | Losartan | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | | Losartan | hsa04350 | TGF-beta signaling pathway | 4.88E-02 | 1 | P37173 | TGFBR2 | More | | Losartan | hsa04370 | VEGF signaling pathway | 3.06E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | Losartan | hsa04380 | Osteoclast differentiation | 2.05E-03 | 12 | Q9NQC7, Q9UQC2, Q16539, P23458, P06239, P01584, P14778, O75015, Q8WV28, P01375, Q15080, P78324 | CYLD, GAB2, MAPK14, JAK1, LCK, IL1B, IL1R1, FCGR3B, BLNK, TNF, NCF4, SIRPA | More | | Losartan | hsa04390 | Hippo signaling pathway | 2.11E-03 | 6 | P63261, Q13485, O15105, Q9UJU2, O43623, Q13489 | ACTG1, SMAD4, SMAD7, LEF1, SNAI2, BIRC3 | More | | Losartan | hsa04392 | Hippo signaling pathway - multiple species | 1.51E-02 | 1 | Q13153 | PAK1 | More | | Losartan | hsa04510 | Focal adhesion | 3.21E-02 | 6 | Q15942, P17252, Q13489, P10415, P49767, P63261 | ZYX, PRKCA, BIRC3, BCL2, VEGFC, ACTG1 | More | | Losartan | hsa04520 | Adherens junction | 3.36E-02 | 4 | Q13485, Q9UJU2, O43623, P63261 | SMAD4, LEF1, SNAI2, ACTG1 | More | | Losartan | hsa04530 | Tight junction | 3.60E-03 | 5 | P63261, P16989, P56750, Q92974, Q14247 | ACTG1, CSDA, CLDN17, ARHGEF2, CTTN | More | | Losartan | hsa04540 | Gap junction | 4.76E-02 | 3 | P17252, Q13509, P68371 | PRKCA, TUBB3, TUBB2C | More | | Losartan | hsa04550 | Signaling pathways regulating pluripotency of stem cells | 4.73E-02 | 3 | Q13873, Q02750, Q86SE9 | BMPR2, MAP2K1, PCGF5 | More | | Losartan | hsa04610 | Complement and coagulation cascades | 3.16E-03 | 2 | P00734, P0C0L4 | F2, C4A | More | | Losartan | hsa04612 | Antigen processing and presentation | 1.51E-02 | 7 | P13765, P48382, P26715, P26717, Q13241, O43908, P01732 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A | More | | Losartan | hsa04613 | Neutrophil extracellular trap formation | 2.22E-06 | 23 | P17252, P11215, O60603, P05164, P08246, Q9UM07, Q13547, Q92769, P0C0S5, Q6FI13, Q93077, P62807, P33778, O60814, P68431, P14598, Q15080, P08311, O75015, P21730, P21462, O43315, Q16539 | PRKCA, ITGAM, TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, H2AFZ, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC3, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q15722 | LTB4R | Leukotriene B4 receptor 1 | P17252 | PRKCA | Protein kinase C alpha type | -0.757 | P51684 | CCR6 | C-C chemokine receptor type 6 | P17252 | PRKCA | Protein kinase C alpha type | 0.738 | Q99527 | GPER1 | G-protein coupled estrogen receptor 1 | P11215 | ITGAM | Integrin alpha-M | 0.734 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O60603 | TLR2 | Toll-like receptor 2 | 0.842 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | O60603 | TLR2 | Toll-like receptor 2 | 0.942 | P51684 | CCR6 | C-C chemokine receptor type 6 | O60603 | TLR2 | Toll-like receptor 2 | -0.767 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P05164 | MPO | Myeloperoxidase | 0.719 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P05164 | MPO | Myeloperoxidase | 0.805 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P08246 | ELA2 | Neutrophil elastase | 0.702 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P08246 | ELA2 | Neutrophil elastase | 0.846 | P51684 | CCR6 | C-C chemokine receptor type 6 | P08246 | ELA2 | Neutrophil elastase | -0.706 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | 0.813 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | 0.799 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.7 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q92769 | HDAC2 | Histone deacetylase 2 | -0.7 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q92769 | HDAC2 | Histone deacetylase 2 | 0.702 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P0C0S5 | H2AFZ | Histone H2A.Z | 0.785 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | Q6FI13 | H2AC18; H2AC19 | Histone H2A type 2-A | 0.833 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q6FI13 | H2AC18; H2AC19 | Histone H2A type 2-A | -0.86 | P11712 | CYP2C9 | Cytochrome P450 2C9 | Q93077 | HIST1H2AC | Histone H2A type 1-C | 0.754 | P11712 | CYP2C9 | Cytochrome P450 2C9 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | 0.717 | Q99527 | GPER1 | G-protein coupled estrogen receptor 1 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | 0.753 | P51684 | CCR6 | C-C chemokine receptor type 6 | P33778 | H2BC3 | Histone H2B type 1-B | 0.704 | P11712 | CYP2C9 | Cytochrome P450 2C9 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | 0.717 | Q99527 | GPER1 | G-protein coupled estrogen receptor 1 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | 0.753 | P11712 | CYP2C9 | Cytochrome P450 2C9 | O60814 | H2BC12 | Histone H2B type 1-K | 0.728 | Q99527 | GPER1 | G-protein coupled estrogen receptor 1 | O60814 | H2BC12 | Histone H2B type 1-K | 0.793 | P11712 | CYP2C9 | Cytochrome P450 2C9 | P68431 | H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | Histone H3.1 | 0.845 | P51684 | CCR6 | C-C chemokine receptor type 6 | P14598 | NCF1 | Neutrophil cytosol factor 1 | -0.713 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q15080 | NCF4 | Neutrophil cytosol factor 4 | 0.762 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | Q15080 | NCF4 | Neutrophil cytosol factor 4 | 0.918 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q15080 | NCF4 | Neutrophil cytosol factor 4 | -0.803 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P08311 | CTSG | Cathepsin G | 0.744 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.92 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.737 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 0.983 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 0.875 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P21462 | FPR1 | fMet-Leu-Phe receptor | 0.839 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P21462 | FPR1 | fMet-Leu-Phe receptor | 0.888 | P51684 | CCR6 | C-C chemokine receptor type 6 | P21462 | FPR1 | fMet-Leu-Phe receptor | -0.7 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O43315 | AQP9 | Aquaporin-9 | 0.934 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | O43315 | AQP9 | Aquaporin-9 | 0.79 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.883 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.721 |
| Losartan | hsa04614 | Renin-angiotensin system | 7.48E-03 | 4 | P50052, P15144, P08311, O75787 | AGTR2, ANPEP, CTSG, ATP6AP2 | More | | Losartan | hsa04623 | Cytosolic DNA-sensing pathway | 1.65E-02 | 2 | P01584, Q8NHW4 | IL1B, CCL4L2 | More | | Losartan | hsa04625 | C-type lectin receptor signaling pathway | 2.53E-03 | 10 | Q9ULY5, Q13153, P01584, Q9NQC7, P20749, Q14643, P01375, Q13191, P0DP24, Q16539 | CLEC4E, PAK1, IL1B, CYLD, BCL3, ITPR1, TNF, CBLB, CALM2, MAPK14 | More | | Losartan | hsa04640 | Hematopoietic cell lineage | 9.72E-05 | 16 | P13612, P14778, P27930, P11215, P15144, P11836, P25063, P07766, P09693, P01732, P01730, P09564, P13765, P01375, P09603, P01584 | ITGA4, IL1R1, IL1R2, ITGAM, ANPEP, MS4A1, CD24, CD3E, CD3G, CD8A, CD4, CD7, HLA-DOB, TNF, CSF1, IL1B | More | | Losartan | hsa04650 | Natural killer cell mediated cytotoxicity | 3.38E-10 | 17 | P16298, P50591, P19174, P01375, P78314, P06239, O60880, P20963, P42338, Q02750, Q13153, Q13241, P26718, O14931, O75015, P26717, P26715 | PPP3CB, TNFSF10, PLCG1, TNF, SH3BP2, LCK, SH2D1A, CD247, PIK3CB, MAP2K1, PAK1, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q05397 | PTK2 | Focal adhesion kinase 1 | P16298 | PPP3CB | Serine/threonine-protein phosphatase 2B catalytic subunit beta isoform | 0.919 | Q05397 | PTK2 | Focal adhesion kinase 1 | P50591 | TNFSF10 | Tumor necrosis factor ligand superfamily member 10 | 0.849 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01375 | TNF | Tumor necrosis factor | 0.78 | P11766 | ADH5 | Alcohol dehydrogenase class-3 | P01375 | TNF | Tumor necrosis factor | -0.709 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.761 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.748 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.823 | Q13547 | HDAC1 | Histone deacetylase 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.786 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.751 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.788 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.786 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | Q13547 | HDAC1 | Histone deacetylase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.774 | Q05397 | PTK2 | Focal adhesion kinase 1 | Q02750 | MAP2K1 | Dual specificity mitogen-activated protein kinase kinase 1 | 0.898 | Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | 1 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.82 | Q13547 | HDAC1 | Histone deacetylase 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.807 | P11766 | ADH5 | Alcohol dehydrogenase class-3 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.726 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.715 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.701 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.91 | Q13547 | HDAC1 | Histone deacetylase 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.772 | P11766 | ADH5 | Alcohol dehydrogenase class-3 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.71 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.842 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.81 | Q13547 | HDAC1 | Histone deacetylase 1 | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.735 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.92 | P11766 | ADH5 | Alcohol dehydrogenase class-3 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | -0.833 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.913 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.896 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.846 | P11766 | ADH5 | Alcohol dehydrogenase class-3 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | 0.737 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.846 | P11766 | ADH5 | Alcohol dehydrogenase class-3 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | 0.737 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 |
| Losartan | hsa04657 | IL-17 signaling pathway | 4.37E-04 | 8 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375, P01584 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF, IL1B | More | | Losartan | hsa04658 | Th1 and Th2 cell differentiation | 5.15E-07 | 15 | Q04759, P07766, P20963, P09693, Q16539, P19174, P01730, P06239, Q14765, P23771, Q9UL17, P14784, P13765, P23458, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, PLCG1, CD4, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, JAK1, RUNX3 | More | | Losartan | hsa04659 | Th17 cell differentiation | 6.07E-06 | 15 | Q04759, Q16539, P19174, P01730, P06239, P14784, P13765, P14778, Q9UL17, P23771, P01584, P07766, P09693, P20963, P23458 | PRKCQ, MAPK14, PLCG1, CD4, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, IL1B, CD3E, CD3G, CD247, JAK1 | More | | Losartan | hsa04660 | T cell receptor signaling pathway | 1.42E-07 | 15 | P01375, Q04759, P42338, O95267, Q08881, P19174, Q13153, P07766, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, PRKCQ, PIK3CB, RASGRP1, ITK, PLCG1, PAK1, CD3E, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01375 | TNF | Tumor necrosis factor | 0.78 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | Q13547 | HDAC1 | Histone deacetylase 1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.723 | Q13547 | HDAC1 | Histone deacetylase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.774 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.852 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.716 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.866 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.746 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | Q13153 | PAK1 | Serine/threonine-protein kinase PAK 1 | 1 | Q13547 | HDAC1 | Histone deacetylase 1 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.802 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.786 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.835 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.77 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.781 | Q13547 | HDAC1 | Histone deacetylase 1 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.816 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.722 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.803 | Q13547 | HDAC1 | Histone deacetylase 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.806 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.719 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.734 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.883 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.889 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.795 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.812 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.861 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 |
| Losartan | hsa04662 | B cell receptor signaling pathway | 1.49E-03 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | Losartan | hsa04664 | Fc epsilon RI signaling pathway | 2.32E-02 | 3 | P42338, P07948, P09917 | PIK3CB, LYN, ALOX5 | More | | Losartan | hsa04666 | Fc gamma R-mediated phagocytosis | 2.22E-02 | 4 | P49006, P06396, P14598, P17252 | MARCKSL1, GSN, NCF1, PRKCA | More | | Losartan | hsa04668 | TNF signaling pathway | 2.91E-02 | 3 | P18848, P01584, P20333 | ATF4, IL1B, TNFRSF1B | More | | Losartan | hsa04714 | Thermogenesis | 3.31E-02 | 4 | P51828, P62753, P12074, O15239 | ADCY7, RPS6, COX6A1, NDUFA1 | More | | Losartan | hsa04720 | Long-term potentiation | 3.93E-05 | 8 | P17252, Q16566, P16298, P0DP23, P51812, O15399, Q02750, Q14643 | PRKCA, CAMK4, PPP3CB, CALM1, RPS6KA3, GRIN2D, MAP2K1, ITPR1 | More | | Losartan | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | | Losartan | hsa04723 | Retrograde endocannabinoid signaling | 1.75E-02 | 5 | Q14643, P17252, P22694, Q16539, Q16718 | ITPR1, PRKCA, PRKACB, MAPK14, NDUFA5 | More | | Losartan | hsa04724 | Glutamatergic synapse | 4.39E-05 | 6 | P48058, O15399, P43003, P63218, P50151, P15104 | GRIA4, GRIN2D, SLC1A3, GNG5, GNG10, GLUL | More | | Losartan | hsa04725 | Cholinergic synapse | 2.49E-03 | 6 | P51828, P63218, P50151, P18848, Q13557, P42338 | ADCY7, GNG5, GNG10, ATF4, CAMK2D, PIK3CB | More | | Losartan | hsa04727 | GABAergic synapse | 1.56E-03 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | | Losartan | hsa04728 | Dopaminergic synapse | 4.12E-03 | 9 | P14416, P63218, P50151, P49841, Q99941, P18848, Q16539, Q13557, P49407 | DRD2, GNG5, GNG10, GSK3B, CREBL1, ATF4, MAPK14, CAMK2D, ARRB1 | More | | Losartan | hsa04750 | Inflammatory mediator regulation of TRP channels | 3.66E-05 | 13 | P14778, P01584, Q08828, P51828, P22694, Q16539, P19174, P42338, Q14643, P24723, Q04759, P0DP24, P0DP23 | IL1R1, IL1B, ADCY1, ADCY7, PRKACB, MAPK14, PLCG1, PIK3CB, ITPR1, PRKCH, PRKCQ, CALM2, CALM1 | More | | Losartan | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | | Losartan | hsa04911 | Insulin secretion | 4.03E-04 | 4 | P51828, Q99941, P18848, Q13557 | ADCY7, CREBL1, ATF4, CAMK2D | More | | Losartan | hsa04912 | GnRH signaling pathway | 1.71E-05 | 10 | P17252, P51828, P18848, Q13557, Q16539, Q9Y6R4, Q14643, P0DP24, P0DP23, P22694 | PRKCA, ADCY7, ATF4, CAMK2D, MAPK14, MAP3K4, ITPR1, CALM2, CALM1, PRKACB | More | | Losartan | hsa04914 | Progesterone-mediated oocyte maturation | 1.00E-02 | 4 | Q17RY0, Q9Y6D9, P51812, Q02750 | CPEB4, MAD1L1, RPS6KA3, MAP2K1 | More | | Losartan | hsa04915 | Estrogen signaling pathway | 4.95E-04 | 9 | Q99941, P18848, Q08828, P51828, P07900, P0DMV8, P11142, P0DP23, Q15788 | CREBL1, ATF4, ADCY1, ADCY7, HSP90AA1, HSPA1A, HSPA8, CALM1, NCOA1 | More | | Losartan | hsa04916 | Melanogenesis | 3.55E-02 | 3 | P0DP23, Q9UJU2, P17252 | CALM1, LEF1, PRKCA | More | | Losartan | hsa04918 | Thyroid hormone synthesis | 1.98E-04 | 5 | P51828, Q99941, P18848, P14625, P02768 | ADCY7, CREBL1, ATF4, HSP90B1, ALB | More | | Losartan | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | | Losartan | hsa04921 | Oxytocin signaling pathway | 4.19E-02 | 4 | P0DP23, P17252, Q16566, P63261 | CALM1, PRKCA, CAMK4, ACTG1 | More | | Losartan | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | Losartan | hsa04925 | Aldosterone synthesis and secretion | 2.88E-06 | 10 | Q14643, Q99941, P18848, P51828, P0DP23, P17252, Q16566, Q13557, P20020, P23634 | ITPR1, CREBL1, ATF4, ADCY7, CALM1, PRKCA, CAMK4, CAMK2D, ATP2B1, ATP2B4 | More | | Losartan | hsa04926 | Relaxin signaling pathway | 5.00E-04 | 8 | P42338, P63218, P50151, Q99941, P18848, P49767, P51828, P49407 | PIK3CB, GNG5, GNG10, CREBL1, ATF4, VEGFC, ADCY7, ARRB1 | More | | Losartan | hsa04927 | Cortisol synthesis and secretion | 4.16E-03 | 3 | Q99941, P18848, P51828 | CREBL1, ATF4, ADCY7 | More | | Losartan | hsa04928 | Parathyroid hormone synthesis, secretion and action | 3.47E-03 | 8 | Q14643, P51828, P22694, P23771, P17252, Q99941, P18848, P10415 | ITPR1, ADCY7, PRKACB, GATA3, PRKCA, CREBL1, ATF4, BCL2 | More | | Losartan | hsa04929 | GnRH secretion | 4.62E-02 | 2 | P42338, P49407 | PIK3CB, ARRB1 | More | | Losartan | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | | Losartan | hsa04932 | Non-alcoholic fatty liver disease | 7.37E-06 | 10 | P01375, P49841, O43521, P18848, P48023, O75460, P01584, P13073, P12074, O95298 | TNF, GSK3B, BCL2L11, ATF4, FASLG, ERN1, IL1B, COX4I1, COX6A1, NDUFC2 | More | | Losartan | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 3.36E-02 | 4 | Q13485, P10415, P49767, P17252 | SMAD4, BCL2, VEGFC, PRKCA | More | | Losartan | hsa04934 | Cushing syndrome | 1.12E-03 | 4 | Q99941, P18848, P51828, Q13557 | CREBL1, ATF4, ADCY7, CAMK2D | More | | Losartan | hsa04935 | Growth hormone synthesis, secretion and action | 2.72E-02 | 3 | P51828, Q99941, P18848 | ADCY7, CREBL1, ATF4 | More | | Losartan | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Losartan | hsa04962 | Vasopressin-regulated water reabsorption | 1.80E-02 | 2 | P62491, P46459 | RAB11A, NSF | More | | Losartan | hsa04966 | Collecting duct acid secretion | 3.15E-02 | 2 | P02730, Q9Y666 | SLC4A1, SLC12A7 | More | | Losartan | hsa04970 | Salivary secretion | 1.12E-04 | 7 | Q08828, P51828, Q14643, P20020, P23634, P17252, P0DP23 | ADCY1, ADCY7, ITPR1, ATP2B1, ATP2B4, PRKCA, CALM1 | More | | Losartan | hsa04971 | Gastric acid secretion | 4.76E-02 | 3 | P17252, P63261, P0DP23 | PRKCA, ACTG1, CALM1 | More | | Losartan | hsa04972 | Pancreatic secretion | 1.00E-02 | 3 | Q14643, P20020, P17252 | ITPR1, ATP2B1, PRKCA | More | | Losartan | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Losartan | hsa04976 | Bile secretion | 2.51E-03 | 5 | Q08828, P51828, P22694, P08183, Q14032 | ADCY1, ADCY7, PRKACB, ABCB1, BAAT | More | | Losartan | hsa04978 | Mineral absorption | 3.94E-02 | 2 | P23634, Q9BXS9 | ATP2B4, SLC26A6 | More | | Losartan | hsa05010 | Alzheimer disease | 2.78E-02 | 6 | P13073, O75460, P0DP24, P01584, P18848, P05141 | COX4I1, ERN1, CALM2, IL1B, ATF4, SLC25A5 | More | | Losartan | hsa05012 | Parkinson disease | 3.89E-02 | 5 | P13073, P05141, O75460, P18848, P0DP24 | COX4I1, SLC25A5, ERN1, ATF4, CALM2 | More | | Losartan | hsa05014 | Amyotrophic lateral sclerosis | 4.31E-02 | 7 | O15399, P10415, Q13509, P68371, Q53GS7, P63261, Q9GZY0 | GRIN2D, BCL2, TUBB3, TUBB2C, GLE1, ACTG1, NXF2; NXF2B | More | | Losartan | hsa05016 | Huntington disease | 3.74E-03 | 10 | O95298, P13073, P12074, P24928, P30876, P62487, P05141, O75460, P28070, O00232 | NDUFC2, COX4I1, COX6A1, POLR2A, POLR2B, POLR2G, SLC25A5, ERN1, PSMB4, PSMD12 | More | | Losartan | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.98E-02 | 7 | P13073, O75460, P18848, P05141, P20333, P01584, P0DP24 | COX4I1, ERN1, ATF4, SLC25A5, TNFRSF1B, IL1B, CALM2 | More | | Losartan | hsa05030 | Cocaine addiction | 4.87E-02 | 2 | Q99941, P18848 | CREBL1, ATF4 | More | | Losartan | hsa05031 | Amphetamine addiction | 2.72E-04 | 7 | O15399, P0DP23, Q16566, Q13557, Q99941, P18848, P17252 | GRIN2D, CALM1, CAMK4, CAMK2D, CREBL1, ATF4, PRKCA | More | | Losartan | hsa05034 | Alcoholism | 3.90E-04 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Losartan | hsa05100 | Bacterial invasion of epithelial cells | 2.85E-02 | 3 | Q14141, Q05397, Q96JJ3 | SEPT6, PTK2, ELMO2 | More | | Losartan | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.35E-06 | 8 | Q16539, Q13153, P09341, P19875, P19174, P25024, P25025, P07948 | MAPK14, PAK1, CXCL1, CXCL2, PLCG1, CXCR1, CXCR2, LYN | More | | Losartan | hsa05132 | Salmonella infection | 2.12E-04 | 13 | P51617, Q9UJU2, P63261, Q13546, Q13489, P10415, O75369, O60603, Q9BQS8, P51808, Q13561, Q13509, P68371 | IRAK1, LEF1, ACTG1, RIPK1, BIRC3, BCL2, FLNB, TLR2, FYCO1, DYNLT3, DCTN2, TUBB3, TUBB2C | More | | Losartan | hsa05133 | Pertussis | 1.25E-03 | 4 | P0DP23, P23528, P09871, P0C0L4 | CALM1, CFL1, C1S, C4A | More | | Losartan | hsa05134 | Legionellosis | 8.80E-04 | 7 | P01584, Q9NR31, P11215, P0DMV8, P11142, P09341, P19875 | IL1B, SAR1A, ITGAM, HSPA1A, HSPA8, CXCL1, CXCL2 | More | | Losartan | hsa05135 | Yersinia infection | 6.38E-03 | 9 | Q05397, P51812, P13612, P06239, Q16539, Q02750, P01375, P49841, Q96JJ3 | PTK2, RPS6KA3, ITGA4, LCK, MAPK14, MAP2K1, TNF, GSK3B, ELMO2 | More | | Losartan | hsa05140 | Leishmaniasis | 1.10E-04 | 12 | P13612, O75015, P14598, P23458, P13765, O60603, P01375, P01584, P49006, Q16539, P51617, Q15080 | ITGA4, FCGR3B, NCF1, JAK1, HLA-DOB, TLR2, TNF, IL1B, MARCKSL1, MAPK14, IRAK1, NCF4 | More | | Losartan | hsa05143 | African trypanosomiasis | 3.01E-03 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | | Losartan | hsa05144 | Malaria | 1.35E-04 | 6 | P60033, O60603, P01375, P35443, P01584, P26718 | CD81, TLR2, TNF, THBS4, IL1B, KLRK1 | More | | Losartan | hsa05146 | Amoebiasis | 4.45E-07 | 14 | P01584, Q13751, P09341, P19875, P14778, P27930, P01375, O60603, P42338, P11215, P05089, P22694, P12814, P08311 | IL1B, LAMB3, CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, PIK3CB, ITGAM, ARG1, PRKACB, ACTN1, CTSG | More | | Losartan | hsa05152 | Tuberculosis | 1.26E-02 | 8 | Q13488, O75015, P48382, O60603, P10415, P13765, Q9UDY8, Q16539 | TCIRG1, FCGR3B, RFX5, TLR2, BCL2, HLA-DOB, MALT1, MAPK14 | More | | Losartan | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | | Losartan | hsa05161 | Hepatitis B | 3.34E-02 | 3 | Q99941, P18848, P27348 | CREBL1, ATF4, YWHAQ | More | | Losartan | hsa05162 | Measles | 3.18E-02 | 4 | P23458, P0DMV8, P01584, Q9NP90 | JAK1, HSPA1A, IL1B, RAB9B | More | | Losartan | hsa05163 | Human cytomegalovirus infection | 2.09E-04 | 17 | P01375, P63218, P50151, Q14643, P0DP23, Q8NHW4, Q08828, P51828, P23458, P49841, P14778, P01584, Q13651, P25025, Q16539, P04637, O00463 | TNF, GNG5, GNG10, ITPR1, CALM1, CCL4L2, ADCY1, ADCY7, JAK1, GSK3B, IL1R1, IL1B, IL10RA, CXCR2, MAPK14, TP53, TRAF5 | More | | Losartan | hsa05168 | Herpes simplex virus 1 infection | 1.94E-02 | 9 | Q9UKJ0, P01568, Q9GZY0, Q01130, Q13489, Q13398, Q03923, Q9UDV6, P10415 | PILRB, IFNA21, NXF2; NXF2B, SFRS2, BIRC3, ZNF211, ZNF85, ZNF212, BCL2 | More | | Losartan | hsa05169 | Epstein-Barr virus infection | 2.60E-04 | 16 | P13765, Q13547, Q92769, P04637, Q13546, P10415, P42338, P07948, Q13761, P24522, O75293, O60603, P29728, P51617, P07766, P09693 | HLA-DOB, HDAC1, HDAC2, TP53, RIPK1, BCL2, PIK3CB, LYN, RUNX3, GADD45A, GADD45B, TLR2, OAS2, IRAK1, CD3E, CD3G | More | | Losartan | hsa05170 | Human immunodeficiency virus 1 infection | 6.54E-03 | 9 | P0DP23, P17252, Q13546, Q14643, P51617, O60603, P09693, P10415, Q9Y6Q5 | CALM1, PRKCA, RIPK1, ITPR1, IRAK1, TLR2, CD3G, BCL2, AP1M2 | More | | Losartan | hsa05171 | Coronavirus disease - COVID-19 | 4.36E-05 | 8 | P23396, P62753, P62249, P62906, P27635, Q07020, P46776, P61513 | RPS3, RPS6, RPS16, RPL10A, RPL10, RPL18, RPL27A, RPL37A | More | | Losartan | hsa05200 | Pathways in cancer | 2.37E-03 | 18 | P04637, Q9UJU2, P17252, Q09472, P43246, Q13485, P14923, P10415, Q13489, Q13077, P49767, P25116, O95267, P78417, P24522, P0DP23, P01568, P16871 | TP53, LEF1, PRKCA, EP300, MSH2, SMAD4, JUP, BCL2, BIRC3, TRAF1, VEGFC, F2R, RASGRP1, GSTO1, GADD45A, CALM1, IFNA21, IL7R | More | | Losartan | hsa05202 | Transcriptional misregulation in cancer | 9.78E-06 | 22 | Q12778, Q15532, P41732, P17844, P14780, P27930, P14923, Q16548, Q13489, Q13077, O15550, P04637, P35226, P05164, P12838, P08246, Q9C0K0, P41182, Q13547, Q92769, P12980, P24522 | FOXO1, SS18, TSPAN7, DDX5, MMP9, IL1R2, JUP, BCL2A1, BIRC3, TRAF1, UTX, TP53, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, HDAC1, HDAC2, LYL1, GADD45A | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q15722 | LTB4R | Leukotriene B4 receptor 1 | Q12778 | FOXO1 | Forkhead box protein O1 | -0.769 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | Q15532 | SS18 | Protein SSXT | -0.803 | P32248 | CCR7 | C-C chemokine receptor type 7 | Q15532 | SS18 | Protein SSXT | 0.804 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P41732 | TSPAN7 | Tetraspanin-7 | 0.775 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P17844 | DDX5 | Probable ATP-dependent RNA helicase DDX5 | 0.863 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P14780 | MMP9 | Matrix metalloproteinase-9 | 0.94 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P14780 | MMP9 | Matrix metalloproteinase-9 | 0.861 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P27930 | IL1R2 | Interleukin-1 receptor type 2 | 0.926 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P27930 | IL1R2 | Interleukin-1 receptor type 2 | 0.734 | P32248 | CCR7 | C-C chemokine receptor type 7 | P14923 | JUP | Junction plakoglobin | 0.711 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.958 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.837 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.797 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.796 | P32248 | CCR7 | C-C chemokine receptor type 7 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | 0.748 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | O15550 | UTX | Lysine-specific demethylase 6A | 0.789 | P32248 | CCR7 | C-C chemokine receptor type 7 | O15550 | UTX | Lysine-specific demethylase 6A | -0.715 | P32248 | CCR7 | C-C chemokine receptor type 7 | P04637 | TP53 | Cellular tumor antigen p53 | 0.77 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.778 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.779 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.778 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P35226 | BMI1 | Polycomb complex protein BMI-1 | -0.779 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P05164 | MPO | Myeloperoxidase | 0.719 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P05164 | MPO | Myeloperoxidase | 0.805 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P12838 | DEFA4 | Neutrophil defensin 4 | 0.784 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P08246 | ELA2 | Neutrophil elastase | 0.702 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P08246 | ELA2 | Neutrophil elastase | 0.846 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | -0.783 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | -0.808 | P32248 | CCR7 | C-C chemokine receptor type 7 | Q9C0K0 | BCL11B | B-cell lymphoma/leukemia 11B | 0.72 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P41182 | BCL6 | B-cell lymphoma 6 protein | 0.919 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.7 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q92769 | HDAC2 | Histone deacetylase 2 | -0.7 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P12980 | LYL1 | Protein lyl-1 | 0.784 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.819 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.764 | P32248 | CCR7 | C-C chemokine receptor type 7 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.862 |
| Losartan | hsa05203 | Viral carcinogenesis | 2.01E-04 | 7 | Q99941, P18848, P27348, Q15283, P61978, P62807, O60814 | CREBL1, ATF4, YWHAQ, RASA2, HNRPK, HIST1H2BC, H2BC12 | More | | Losartan | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Losartan | hsa05210 | Colorectal cancer | 2.69E-03 | 6 | Q9UKG1, P10415, P04637, Q9UJU2, P37173, P24522 | APPL1, BCL2, TP53, LEF1, TGFBR2, GADD45A | More | | Losartan | hsa05211 | Renal cell carcinoma | 2.42E-02 | 1 | Q13153 | PAK1 | More | | Losartan | hsa05212 | Pancreatic cancer | 3.40E-02 | 1 | P37173 | TGFBR2 | More | | Losartan | hsa05213 | Endometrial cancer | 1.91E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Losartan | hsa05214 | Glioma | 8.71E-04 | 5 | P0DP23, Q16566, P17252, P04637, P24522 | CALM1, CAMK4, PRKCA, TP53, GADD45A | More | | Losartan | hsa05215 | Prostate cancer | 1.97E-03 | 6 | P10415, Q9UJU2, Q09472, P04637, P18848, P14625 | BCL2, LEF1, EP300, TP53, ATF4, HSP90B1 | More | | Losartan | hsa05216 | Thyroid cancer | 2.42E-04 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Losartan | hsa05217 | Basal cell carcinoma | 2.82E-04 | 5 | Q13635, P49841, Q9UJU2, P04637, P24522 | PTCH1, GSK3B, LEF1, TP53, GADD45A | More | | Losartan | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | Losartan | hsa05222 | Small cell lung cancer | 1.94E-02 | 4 | P10415, Q13077, P04637, P24522 | BCL2, TRAF1, TP53, GADD45A | More | | Losartan | hsa05224 | Breast cancer | 5.34E-03 | 5 | Q9UJU2, P49841, Q92837, P04637, P24522 | LEF1, GSK3B, FRAT1, TP53, GADD45A | More | | Losartan | hsa05226 | Gastric cancer | 8.86E-03 | 5 | Q9UJU2, P04637, P24522, P14923, P10415 | LEF1, TP53, GADD45A, JUP, BCL2 | More | | Losartan | hsa05230 | Central carbon metabolism in cancer | 4.04E-02 | 2 | P07195, P04637 | LDHB, TP53 | More | | Losartan | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 2.22E-04 | 12 | P42338, O95267, P19174, P07766, P20963, P09693, P06239, P23458, O60603, Q04759, Q16539, P01730 | PIK3CB, RASGRP1, PLCG1, CD3E, CD247, CD3G, LCK, JAK1, TLR2, PRKCQ, MAPK14, CD4 | More | | Losartan | hsa05321 | Inflammatory bowel disease | 1.19E-03 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, P01584 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL1B | More | | Losartan | hsa05322 | Systemic lupus erythematosus | 1.49E-05 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Losartan | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | | Losartan | hsa05332 | Graft-versus-host disease | 1.27E-04 | 6 | P13765, P48023, P10747, P01375, P26715, Q13241 | HLA-DOB, FASLG, CD28, TNF, KLRC1, KLRD1 | More | | Losartan | hsa05415 | Diabetic cardiomyopathy | 4.23E-02 | 2 | P30405, P37173 | PPIF, TGFBR2 | More | | Losartan | hsa05418 | Fluid shear stress and atherosclerosis | 2.06E-04 | 12 | Q16539, P78417, P10599, P14780, P01375, P63261, P04637, P10415, P14778, P27930, P0DP23, Q92974 | MAPK14, GSTO1, TXN, MMP9, TNF, ACTG1, TP53, BCL2, IL1R1, IL1R2, CALM1, ARHGEF2 | More | | |